[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies in Neurology
August 2001

The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta

Author Affiliations

From the Multiple Sclerosis Clinic, University of Western Ontario, London.

 

JOHN N.WHITAKERMD

Arch Neurol. 2001;58(8):1297-1298. doi:10.1001/archneur.58.8.1297

THE DEVELOPMENT of neutralizing antibodies (NABs) against interferons is well described in patients with viral hepatitis and with some cancers that are treated with interferon.1 In patients with hepatitis or cancer, the development of NABs has been associated with reduction of interferon-related adverse effects (eg, fever, chills, and myalgia) and with the recurrence of disease activity. Treatment failure due to NABs in such patients has been much easier to identify, by measuring the more sensitive disease activity markers (eg, transaminase levels in patients with hepatitis or tumor or tumor markers in patients with cancer).

First Page Preview View Large
First page PDF preview
First page PDF preview
×